Aldi Recall Alert: Hidden Allergens in Two Products Sold in 16 States

If you've shopped at Aldi recently, it might be time to double-check your freezer. The budget grocery giant has issued two new food recalls affecting 16 states. The recall comes after potential allergen risks were discovered in products sold under its private label brands.
The first recall involves Casa Mamita Churro Bites Filled with Chocolate Hazelnut Cream. According to the U.S. Food and Drug Administration, the product may contain undeclared milk, a major allergen.
The affected churro bites come in 7.05-ounce cardboard boxes marked with UPC Code 4061459561807 and a "Best If Used By" date of July 14, 2026. While no illnesses have been reported, customers with milk allergies are advised not to consume the product and instead return it to Aldi for a full refund.
This product was distributed in 13 states: Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina, and Tennessee.
The second recall affects Atlantic Salmon Portions with Seafood Stuffing, manufactured by Santa Monica Seafood. This item was sold in 16-ounce packages with UPC Code 4061459716313 and a use/freeze-by date of June 2, 2025. It was distributed to Aldi locations in California, Nevada, and Arizona. The product may contain undeclared soy, another top allergen that can cause serious reactions for sensitive individuals.
For customers with food allergies, these undeclared ingredients pose a serious health risk. Dr. Sebastian Lighvani, a New York-based allergist, explained to Newsweek that even trace amounts of allergens like milk or soy can trigger immune responses in susceptible individuals. They could lead to potentially life-threatening reactions.
Aldi emphasized its commitment to consumer safety in a statement, directing concerned customers to their recall page and offering full refunds on returned products.
Whether you have known allergies or not, it's worth taking a moment to check your fridge and freezer. Recalls like these are a reminder of how vital food labeling and consumer awareness are, especially when it comes to the ingredients we can't see.
Aldi Recall Alert: Hidden Allergens in Two Products Sold in 16 States first appeared on Men's Journal on Jun 11, 2025

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

One Weight Loss Strategy Is 5x More Effective Than Ozempic, Trials Show

Ozempic and other semaglutide medications have been working wonders in terms of shedding pounds for many people, but a new study shows that they're still not as effective as surgery when it comes to weight loss – and it's not even close. Researchers from New York University (NYU) compared sleeve gastrectomy and gastric bypass operations against semaglutide or tirzepatide. These drugs are known as glucagon-like peptide-1 (GLP-1) receptor agonists, because of the way they mimic the natural GLP-1 hormone, which controls appetite. Using health records, the team matched people who had taken one of the weight loss drugs with people who had undergone either of the bariatric surgery operations, based on age, body mass index, and blood sugar levels. The bottom line: people in the surgery group shed an average of 25.7 percent of their total body weight over two years, while those in the medication group lost 5.3 percent. That's partly down to patients not sticking to their GLP-1 drugs, whereas surgery is more permanent, but the researchers also noticed smaller differences over shorter time frames – the surgery always gave the best results. "Clinical trials show weight loss between 15 percent to 21 percent for GLP-1s, but this study suggests that weight loss in the real world is considerably lower even for patients who have active prescriptions for an entire year," says Avery Brown, a surgical resident at NYU Langone Health. "We know as many as 70 percent of patients may discontinue treatment within one year. GLP-1 patients may need to adjust their expectations, adhere more closely to treatment or opt for metabolic and bariatric surgery to achieve desired results." It's worth noting, however, that the study was funded by the American Society for Metabolic and Bariatric Surgery (ASMBS), who would have a vested interest in promoting surgical options. That said, the researchers aren't outright dismissing semaglutide treatments, which also showed beneficial results in this study. With GLP-1 prescriptions doubling from 2022 to 2023, it's crucial to investigate how they compare to established surgery methods, and to figure out which options are best for each individual. GLP-1 drugs remain much more popular than surgery, but people don't often stick to taking them. Meanwhile, only a small percentage of people eligible for surgery choose it as an option. Weight loss isn't the only benefit that can come from Ozempic. The drug was originally approved as a way to treat type 2 diabetes, because it helps lower blood sugar levels, and studies have shown it can also reduce the risk of cancer and cardiovascular disease. In this study, bariatric surgery was associated with even better blood sugar control. It's also important to note that surgery isn't a silver bullet either. Though safe, the procedures are invasive, permanent, and still require patients to stick to strict diet and exercise routines. "In future studies we will aim to identify what healthcare providers can do to optimize GLP-1 outcomes, identify which patients are better treated with bariatric surgery versus GLP-1s, and determine the role out-of-pocket costs play in treatment success," says Karan Chhabra, a bariatric surgeon at the NYU Grossman School of Medicine. The research was presented at the ASMBS annual meeting 2025. There's a Shocking Reason Ticks Are So Dangerous (It's Us) Cannabis Linked to 2x Risk of Heart Disease Death, Scientists Discover 5 Daily Habits Could Be Causing Your Liver Serious Harm

Yahoo

8 hours ago

• Yahoo

Rare dual-hospital campus in Ogdensburg seeks continued support from state

Jun. 21—OGDENSBURG — As North Star Health Alliance completes its plan for preserving rural healthcare in the north country, it is looking for continued strong support from the state to help it reach the final phase in the transformation of its Ogdensburg campus. Since August 2022, North Star has been working with the state Department of Health on a stabilization plan that unites Claxton-Hepburn Medical Center, Carthage Area Hospital, Claxton-Hepburn Medical Campus, North Country Orthopaedic Group and Meadowbrook Terrace under a shared framework for leadership and service coordination. Central to this transformation, according to North Star, is a pioneering Ogdensburg campus where two separately licensed hospitals operate side by side under one roof, a first in New York state. Claxton-Hepburn Medical Center now serves as a 40-bed inpatient psychiatric hospital, which North Star says is the first stand-alone, not-for-profit facility of its kind in the state, with dedicated units tailored for children, adolescents and adults. Adjacent to this is the Claxton-Hepburn Medical Campus, a 25-bed acute care hospital managed by Carthage Area Hospital that has completed the final steps for Critical Access Hospital status. It was previously a 137-bed acute care hospital. In June 2024, the state's Public Health and Health Planning Council voted unanimously to approve the dual-hospital plan, praising it as a model for other rural healthcare systems, according to North Star President and CEO Richard A. Duvall. "It's the first one in New York State to have a single campus with two hospitals on it," Duvall said. "It has been nationally, but never in New York. All of this creates a sustainable model for the future of securing rural health care." Duvall said the separation of the behavioral health unit has improved the traffic flow and patient experience in the emergency room. "Instead of having the ER doctor whose got an appendix case here, cardiology case there, and then someone in behavioral health crisis over there, it allows for that more individualize, or specialized care. It speeds up the patient experience quite a bit too." The Claxton Campus successfully completed its critical access survey on June 12, marking an important final milestone in the designation process, which Duvall said will move North Star confidently into the next phase of it strategic plan, focused on strengthening rural healthcare access and sustainability across the north country by better allowing for clinical integration, resource sharing and joint planning, all vital in a rural region. In addition, North Star's member organizations support over 1,800 jobs across the region and generate $307 million in annual economic activity. In 2024, North Star's facilties handled more than 325,000 outpatient appointments, 31,000 emergency department visits, 5,000 hospital admissions and welcomed 530 newborns. He said the changes were made without cutting staff or services. "This is a good news story," he said. Duvall said all of North Star's accomplishments have come with the strong backing of the state, from the Department of Health up to Gov. Kathleen C. Hochul. Duvall said the governor and DOH's leadership have been unwavering in support of North Star's efforts. Now, North Star is looking to the state to help with a final piece of its transition and stabilization plan. It was recently invited to apply for funding through Gov. Hochul's Safety Net Trasnformation Program, which was established in the state's Fiscal Year 2025 Enacted Budget to provide, among other things, both capital and operating resources to safety net hospitals in vulnerable communities. Duvall said if North Star's application is successful, the state funding would enable essential facility upgrades and offset temporary revenue shortfalls as a the hospitals transition to Critical Access Hospital status. As North Star awaits word on the funding, Duvall expressed the alliance's gratitude to vendors and employees for their continued support during what he concedes is a financially challenging period. He said, however, the changes being made by North Star will not only help preserve healthcare in the region at a time when may rural hospitals are cutting vital services, but allow for the expansion of specialty care while strengthening care delivery across each of the communities where North Star operates.

New York Post

10 hours ago

• New York Post

Nationwide recall issued for popular chocolate brand that contains potentially ‘life-threatening' ingredient

A popular chocolate treat is being pulled from shelves nationwide over an ingredient that may trigger severe – and potentially deadly – allergic reactions, federal officials warned. An urgent recall was issued after Lipari Foods discovered that its 14-ounce packages of JLM Branded Dark Chocolate Nonpareils may contain undeclared milk, the US Food and Drug Administration (FDA) announced Friday. Those with milk allergies are urged to avoid consuming the potentially lethal candy. Select packages of JLM Branded Dark Chocolate Nonpareils may contain undeclared milk. USFDA 'People who have allergies to milk run the risk of serious or life-threatening allergic reactions if they consume these products,' the dire bulletin stated. The Michigan-based company initiated the recall after its distributor, Weave Nut Company, alerted them that the candy may contain the dairy allergen, which was not disclosed on the packaging. But the sprinkle-topped chocolate discs, sold in clear plastic tubs, had already made their way to retailers across the country. The recall targets packaging with lot codes 28202501A, 29202501A, 23202504A, 14202505A, 15202505A, and 03202506A on the bottom label. No illnesses or adverse reactions have been reported in connection with the recall. Brent Hofacker – The FDA advised customers to return the product to the place of purchase for a full refund. No illnesses or adverse reactions have been reported in connection with the recall.